Loading...
XNASBCDA
Market cap11mUSD
Dec 27, Last price  
2.46USD
1D
6.03%
1Q
-16.33%
Jan 2017
-84.81%
Name

BioCardia Inc

Chart & Performance

D1W1MN
XNAS:BCDA chart
P/E
—
P/S
23.64
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
37.79%
Rev. gr., 5y
-5.26%
Revenues
477k
-64.72%
3,759,3720001,268,0001,869,000012,00062,000268,000427,000517,000576,000479,000625,000710,000145,0001,015,0001,352,000477,000
Net income
-12m
L-2.87%
-722,704-812,341-92,804-75,444-5,800,000-5,078,000-11,509,0009,662,000305,00019,000234,000322,000-10,310,000-12,308,000-13,872,000-14,819,000-15,005,000-12,621,000-11,913,000-11,571,000
CFO
-10m
L-5.56%
-749,416-455,817-741,464-47,123-2,696,000-4,783,000-4,277,000-3,087,000-310,00027,000214,000331,000-5,522,000-8,671,000-11,069,000-9,445,000-12,357,000-10,366,000-10,561,000-9,974,000
Earnings
Mar 25, 2025

Profile

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
URL
https://www.biocardia.com/
IPO date
Nov 13, 1996
Employees
30
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
477
-64.72%
1,352
33.20%
1,015
600.00%
Cost of revenue
15,452
20,735
9,198
Unusual Expense (Income)
NOPBT
(14,975)
(19,383)
(8,183)
NOPBT Margin
Operating Taxes
6
(2)
Tax Rate
NOPAT
(14,975)
(19,389)
(8,181)
Net income
(11,571)
-2.87%
(11,913)
-5.61%
(12,621)
-15.89%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,388
5,122
2,001
BB yield
-31.19%
-13.83%
-6.10%
Debt
Debt current
666
315
237
Long-term debt
2,297
2,632
3,499
Deferred revenue
Other long-term liabilities
Net debt
1,860
(4,416)
(9,136)
Cash flow
Cash from operating activities
(9,974)
(10,561)
(10,366)
CAPEX
(12)
(70)
(116)
Cash from investing activities
(12)
(70)
(116)
Cash from financing activities
3,726
5,122
1,947
FCF
(12,920)
(19,253)
(9,534)
Balance
Cash
1,103
7,363
12,872
Long term investments
Excess cash
1,079
7,295
12,821
Stockholders' equity
(152,151)
(140,584)
(128,680)
Invested Capital
152,196
147,107
140,923
ROIC
ROCE
EV
Common stock shares outstanding
1,412
1,181
1,128
Price
9.96
-68.22%
31.35
7.73%
29.10
-43.93%
Market cap
14,068
-62.02%
37,037
12.85%
32,820
-6.26%
EV
15,928
32,621
23,684
EBITDA
(14,891)
(19,301)
(8,123)
EV/EBITDA
Interest
6
Interest/NOPBT